Concert Pharmaceuticals (NASDAQ: CNCE)
Some price data may be temporarily unavailable.
Concert Pharmaceuticals Return vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
Concert Pharmaceuticals Company Info
Concert Pharmaceuticals is a clinical-stage biotechnology company dedicated to creating new medicines through a novel scientific approach utilizing the naturally-occurring element deuterium. Concert applies its innovative precision deuterium chemistry platform to modify specific properties of validated drug molecules, yielding a rich pipeline of new chemical entities (NCEs). Concert leverages decades of pharmaceutical experience to create novel drug candidates with the potential for efficacy and safety, while greatly reducing R&D risk, time, and expense.
News & Analysis
Why Concert Pharmaceuticals Stock Rocketed Higher This Week
The company is changing hands in a deal worth at least $576 million.
Why Concert Pharmaceuticals Stock Cratered Today
The company's experimental schizophrenia drug flopped in a phase 2 study.
Why Concert Pharmaceuticals Stock Is Tanking Today
Shares fall hard after a late-stage trial comes up short.
Why Concert Pharmaceuticals, Inc. Is Singing the Blues Today
Bad news trumps good news for the biotech.
Why General Electric, Concert Pharmaceuticals, and NVR Jumped Today
Even on a quiet day on Wall Street, these stocks posted gains. Find out why.
Why Concert Pharmaceuticals Stock Is Soaring Today
The pharma cut a deal with Vertex for the experimental experimental cystic fibrosis drug CTP-656.
Instant Analysis: Vertex Pharmaceuticals Inc Nabs an Approval
The company's newest cystic fibrosis drug has won approval in Australia. Will this move the needle?
Shareholders Breathe Easier as Concert Pharmaceuticals Rockets Higher By 23%
Concert Pharmaceuticals' phase 1 data dazzles when put side by side with a major competitors' FDA-approved cystic fibrosis drug,
Valuation
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.